American Society of peritoneal surface malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer

Journal of Surgical Oncology

Volumn 110, Issue 7, 2014, Pages 777-778

  Esquivel, Jesus ^a   Piso, Pompiliu ^b   Verwaal, Vic ^c   Bachleitner Hofmann, Thomas ^d   Glehen, Olivier ^e   González Moreno, Santiago ^f   Deraco, Marcello ^g   Pelz, Joerg ^h   Alexander, Richard ⁱ   Glockzin, Gabriel ^j  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

^b Barmherzige Brüder Hospital   (Germany)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF VIENNA   (Austria)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f MD ANDERSON CANCER CENTER   (Spain)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY HOSPITAL REGENSBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CHEMOTHERAPY; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MEDICAL SOCIETY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; ABDOMINAL SURGERY; COLORECTAL NEOPLASMS; EXPERT WITNESS; HEALTH CARE ORGANIZATION; HYPERTHERMIC THERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEAL NEOPLASMS; PROGNOSIS; REGIONAL PERFUSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; EXPERT TESTIMONY; HUMANS; HYPERTHERMIA, INDUCED; PERITONEAL NEOPLASMS; PROGNOSIS; SOCIETIES, SCIENTIFIC;

EID: 84922333922     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23722     Document Type: Note

References (5)

1. Elias D, Faron M, Luga B, et al.,: Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. Ann Surg 2014; Feb 6 (Epub ahead of print). PMID 24509197.
2. Klaver YLB, Simkens LHJ, Lemmens VEPP, et al.,: Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with, without targeted therapy. EJSO 2012; 38: 617-623.
3. Turaga K, Levine E, Barone R, et al.,: Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 2014; 21: 1501-1505.
4. Yang XJ, Huang CQ, Suo T, et al.,: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patient's with Peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial. Ann Surg Oncol 2011; 18: 1575-1581.
5. Esquivel J, Lowy A, Markman M, et al.,: The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 patient with colorectal cancer. Ann Surg Oncol 2014; May 23 (Epub ahead of print). PMID 24854493.